Silexion Therapeutics, Evonik collaborate on siRNA formulation development
Silexion Therapeutics (SLXN) revealed its ongoing collaboration with Evonik for the development of an advanced siRNA ...
Pharmabiz10h
Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC
Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...
Armed robbery in Revesby16h
Monash Receives $49m In NHMRC Ideas Grants
Monash University has secured over $49 million in funding for 40 projects in the latest round of NHMRC Ideas Grants - more than any other university ...
Medscape17h
Atezolizumab Plus Neoadjuvant Chemotherapy Fails to Meet Primary Endpoint in Early-Stage TNBC
The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...
precisionmedicineonline19h
Merck to Discontinue Anti-TIGIT, Anti-LAG-3 Programs Based on Lackluster Results
The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.